Abstract library

97 results for "trials".
#1310 Current Trials in Neuroendocrine Tumours: A Systematic Review
Introduction: Trials in neuroendocrine tumours (NETs) have increased markedly in number over the last 10 years. Researchers do not have ready access to a summary of open trials to identify research gaps.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr David Chan
Authors: Chan D, Segelov E, Millican J, Singh S, ...
Keywords: trials, review
#300 Association Between Time to Disease Progression Endpoints and Overall Survival in Patients with Neuroendocrine Tumors
Introduction: While the association between time to disease progression (TDP) and overall survival (OS) has been examined in a variety of cancers, it has not been assessed in trials of neuroendocrine tumors (NETs).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Thomas E Delea
Authors: Delea T E, Rotter J, Wang X, ...
#1449 Promoting High Quality Care in Clinical Trials for Patients with Neuroendocrine Tumors (NETs)
Introduction: The European Institute of Oncology is an ENETS Center of Excellence. Many patients (pts) are treated in clinical trials. The clinical research nurse (CRN) is a key figure in care delivery. Optimising staff resources means some trial activities are delivered by nursing staff with limited research experience. To provide high quality care & accurate trial results, all nursing staff caring for NET pts should have appropriate trial related support and training.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Sara Gazzabin
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C, ...
#992 Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Recently there have been many advances in the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors (GEP NETs), accompanied by significant improvements in our understanding of GEP NET biology. A number of well-established or novel molecular hallmarks are involved in GEP NET tumorigenesis and may help in identifying potential diagnostic or therapeutic targets.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Dr Gianluca Tamagno
#2112 Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Nicola Fazio
Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, ...
#2115 Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: David L Chan
#870 Telotristat Etiprate (TE) in a Cohort of Carcinoid Heart Disease Patients in Two Phase 2 Trials
Introduction: Serotonin is a key mediator of carcinoid syndrome (CS). High levels of urinary 5-hydroxyindoleacetic acid (u5-HIAA, a serotonin metabolite) have also been linked with carcinoid heart disease (CaHD). Telotristat etiprate (TE), a novel, oral inhibitor of serotonin synthesis, is in Phase 3 development for the treatment of CS.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Darren Wheeler
#350 RAD001 and Octreotide LAR as first-line treatment of well differentiated neuroendocrine tumors: an I.T.M.O. (Italian Trials in Medical Oncology) group study
Introduction: RAD001 has shown antitumor activity in pancreatic neuroendocrine tumors (NETs) and it seems to work synergistically with somatostatine analogues.
Conference:
Category: Basic
Presenting Author: Dr Laura Catena
#383 Everolimus and Octreotide LAR in Neuroendocrine Tumors: An I.T.M.O. (Italian Trials in Medical Oncology) Group Study
Introduction: Everolimus has shown antitumor activity in pancreatic neuroendocrine tumors (NETs) and it seems to work synergistically with octreotide.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Emilio Bajetta